Ticker Details
Inovio Pharmaceuticals, Inc. Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.
IPO Date:	August 23, 1999
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$118.86M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.16 | 3.60%
Avg Daily Range (30 D):	$0.05 | 2.95%
Avg Daily Range (90 D):	$0.07 | 3.39%

Institutional Daily Volume
Avg Daily Volume:	.5M
Avg Daily Volume (30 D):	1.1M
Avg Daily Volume (90 D):	1.35M

Trade Size
Avg Trade Size (Sh.):	46
Avg Trade Size (Sh.) (30 D):	257
Avg Trade Size (Sh.) (90 D):	243

Institutional Trades
Total Institutional Trades:	3,231
Avg Institutional Trade:	$1.7M
Avg Institutional Trade (30 D):	$1.67M
Avg Institutional Trade (90 D):	$.96M
Avg Institutional Trade Volume:	.02M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$2.58M
Avg Closing Trade (30 D):	$1.67M
Avg Closing Trade (90 D):	$1.67M
Avg Closing Volume:	49.21K

News

Feb 24, 2026 @ 10:57 PM INOVIO CLASS ACTION ALERT: Bragar Eagel & Squire, ... Source: Bragar Eagel & Squire, P.C.

Feb 24, 2026 @ 5:00 PM DEADLINE ALERT for ORCL, PSFE, INO, KD: Law Office... Source: Law Offices Of Howard G. Smith

Feb 23, 2026 @ 11:34 AM Is Inovio Pharmaceuticals Stock Going to $0? Source: Prosper Junior Bakiny

Feb 23, 2026 @ 12:23 AM ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Enpha... Source: Rosen Law Firm

Feb 22, 2026 @ 2:33 PM ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages I... Source: Rosen Law Firm

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-2.72	$-.87	$-.61
Diluted EPS	$-2.72	$-.87	$-.61
Revenue	$.18M	$M	$M
Gross Profit
Net Income / Loss	$-108.09M	$-45.5M	$-23.52M
Operating Income / Loss	$-89.72M	$-21.21M	$-23.08M
Cost of Revenue
Net Cash Flow	$14.88M	$12.22M	$-15.56M
PE Ratio

Splits
Jan 25, 2024	1:12
Jun 09, 2014	1:4
Jun 06, 2014	1:4
Sep 13, 2004	1:4